{ "labelLang" : "hun", "responseDate" : "2024-03-29 08:21", "content" : { "otype" : "JournalArticle", "mtid" : 31344855, "status" : "APPROVED", "published" : true, "comment" : "Division of diabetes, nutrition and metabolic disorders, department of medicine, CHU Liège, Liège University, Liège, Belgium \n Clinical pharmacology unit, Centre for interdisciplinary research on medicines (CIRM), CHU Liège, Liège University, Liège, Belgium \n Export Date: 22 June 2020 \n CODEN: DIMEF \n Correspondence Address: Scheen, A.J.; Department of medicine, CHU Sart Tilman (B35)Belgium; email: andre.scheen@chuliege.be \n Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; hemoglobin A1c, 62572-11-6; metformin, 1115-70-4, 657-24-9; sotagliflozin, 1018899-04-1\nDivision of diabetes, nutrition and metabolic disorders, department of medicine, CHU Liège, Liège University, Liège, Belgium \n Clinical pharmacology unit, Centre for interdisciplinary research on medicines (CIRM), CHU Liège, Liège University, Liège, Belgium \n Cited By :8 \n Export Date: 9 July 2021 \n CODEN: DIMEF \n Correspondence Address: Scheen, A.J.; Department of medicine, Belgium; email: andre.scheen@chuliege.be \n Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; hemoglobin A1c, 62572-11-6; metformin, 1115-70-4, 657-24-9; sotagliflozin, 1018899-04-1", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2022-05-23T06:50:33.395+0000", "lastModified" : "2020-09-16T06:51:16.288+0000", "created" : "2020-06-15T06:54:30.442+0000", "creator" : { "otype" : "Author", "mtid" : 10003400, "link" : "/api/author/10003400", "label" : "Lengyel Csaba Attila (diabetológia, belgyógyászat)", "familyName" : "Lengyel", "givenName" : "Csaba Attila", "published" : true, "oldId" : 10003400, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Scheen, A. J.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 91857764, "link" : "/api/authorship/91857764", "label" : "Scheen, A. J. ✉", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : true, "familyName" : "Scheen", "givenName" : "A. J.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 16983050, "link" : "/api/publicationidentifier/16983050", "label" : "DOI: 10.1016/j.diabet.2020.01.002", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/j.diabet.2020.01.002", "realUrl" : "https://doi.org/10.1016%2Fj.diabet.2020.01.002", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16983051, "link" : "/api/publicationidentifier/16983051", "label" : "WoS: 000536163400002", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=CustomerName&SrcApp=CustomerName&DestLinkType=FullRecord&KeyUT=@@@&DestApp=WOS", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000536163400002", "realUrl" : "http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=CustomerName&SrcApp=CustomerName&DestLinkType=FullRecord&KeyUT=000536163400002&DestApp=WOS", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17009253, "link" : "/api/publicationidentifier/17009253", "label" : "Scopus: 85078962464", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85078962464", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85078962464", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16983052, "link" : "/api/publicationidentifier/16983052", "label" : "PubMed: 32007623", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "32007623", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32007623&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 11919, "link" : "/api/journal/11919", "label" : "DIABETES & METABOLISM 1262-3636", "pIssn" : "1262-3636", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 11919, "snippet" : true }, "volume" : "46", "issue" : "3", "firstPage" : "186", "lastPage" : "196", "firstPageOrInternalIdForSort" : "186", "pageLength" : 11, "publishedYear" : 2020, "abstractText" : "Aims. - This study compared the reduction of glycated haemoglobin (HbA1c) with sodium-glucose cotransporter type-2 inhibitors (SGLT2is) vs. dipeptidyl peptidase-4 inhibitors (DPP-4is) as add-ons to metformin in patients with type 2 diabetes mellitus (T2DM), with a specific focus on HbA1c changes according to baseline HbA1c. Materials and methods. - Electronic databases were scrutinized for randomized controlled trials (RCTs) evaluating the reduction of HbA1c from baseline (Delta HbA1c) with an SGLT2i or DPP-4i in patients with T2DM not well controlled by metformin monotherapy. The endpoint was Delta HbA1c using both indirect and direct comparisons. Results. - Overall, Delta HbA1c was slightly greater with SGLT2is (-0.80 +/- 0.20% from 8.03 +/- 0.35%; 44 analyses, 29 RCTs, 15 with two doses, n = 9321) than with DPP-4is (-0.71 +/- 0.23% from 8.05 +/- 0.43%; 61 analyses, 59 RCTs, n = 17,914; P= 0.0354). When the mean baseline HbA1c was < 8% ([64 mmol/mol] 7.79 +/- 0.15% vs. 7.71 +/- 0.23%), Delta HbA1c averaged -0.735 +/- 0.17% vs. -0.62 +/- 0.16% (P = 0.0117) with SGLT2is vs. DPP-4is, respectively. However, this difference vanished when the mean baseline HbA1c was >= 8% (-0.87 +/- 0.22% from 8.27 +/- 0.32% with SGLT2is vs. -0.80 +/- 0.24% from 8.35 +/- 0.33% with DPP-4is; P = 0.2756). The relationship between Delta HbA1c and baseline HbA1c was only slightly stronger with SGLT2is (slope: -0.39, r(2) = -0.43; P < 0.0001) than with DPP-4is (slope: -0.26, r(2) = -0.25; P < 0.0001). Conclusion. - Because of the small difference in Delta HbA1c whatever the baseline HbA1c level with SGLT2is vs. DPP-4is as add-ons to metformin, choosing between these glucose-lowering agents in clinical practice should be based on other efficacy criteria (such as weight and blood pressure changes, cardiovascular and renal protection) or on safety profiles rather than on HbA1c levels. (C) 2020 Elsevier Masson SAS. All rights reserved.", "keywords" : [ { "otype" : "Keyword", "mtid" : 1787, "link" : "/api/keyword/1787", "label" : "TYPE-2 DIABETES-MELLITUS", "published" : true, "oldId" : 1787, "snippet" : true }, { "otype" : "Keyword", "mtid" : 17576, "link" : "/api/keyword/17576", "label" : "DOUBLE-BLIND", "published" : true, "oldId" : 17576, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1031389, "link" : "/api/keyword/1031389", "label" : "metformin", "published" : true, "oldId" : 1031389, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1038323, "link" : "/api/keyword/1038323", "label" : "Glucose control", "published" : true, "oldId" : 1038323, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1041645, "link" : "/api/keyword/1041645", "label" : "OPEN-LABEL", "published" : true, "oldId" : 1041645, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1059173, "link" : "/api/keyword/1059173", "label" : "HbA1c", "published" : true, "oldId" : 1059173, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1070036, "link" : "/api/keyword/1070036", "label" : "combination therapy", "published" : true, "oldId" : 1070036, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1409396, "link" : "/api/keyword/1409396", "label" : "DPP-4 inhibitor", "published" : true, "oldId" : 1409396, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1498448, "link" : "/api/keyword/1498448", "label" : "CHINESE PATIENTS", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527309, "link" : "/api/keyword/1527309", "label" : "dipeptidyl peptidase-4 inhibitor", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527426, "link" : "/api/keyword/1527426", "label" : "SGLT2 inhibitor", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1603974, "link" : "/api/keyword/1603974", "label" : "Asian patients", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 2018775, "link" : "/api/keyword/2018775", "label" : "INADEQUATE GLYCEMIC CONTROL", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 2018776, "link" : "/api/keyword/2018776", "label" : "GLUCOSE COTRANSPORTER-2 INHIBITORS", "published" : true, "snippet" : true } ], "digital" : null, "printed" : null, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : null, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2022-05-23", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 1, "citedCount" : 1, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10796557, "link" : "/api/sjrrating/10796557", "label" : "sjr:Q1 (2020) Scopus - Endocrinology DIABETES & METABOLISM 1262-3636", "listPos" : 22, "rankValue" : 0.24, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 1310, "link" : "/api/classificationexternal/1310", "label" : "Scopus - Endocrinology", "published" : true, "oldId" : 1310, "snippet" : true }, "ranking" : "Q1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "Q1", "referenceList" : "Abe T, 2018, DIABETES METAB, V44, P172, DOI 10.1016/j.diabet.2017.10.003 \n Ahren B, 2004, DIABETES CARE, V27, P2874, DOI 10.2337/diacare.27.12.2874 \n Ajmani AK, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107860 \n Amin NB, 2015, DIABETES OBES METAB, V17, P591, DOI 10.1111/dom.12460 \n Arechavaleta R, 2011, DIABETES OBES METAB, V13, P160, DOI 10.1111/j.1463-1326.2010.01334.x \n Aschner P, 2012, LANCET, V379, P2262, DOI 10.1016/S0140-6736(12)60439-5 \n Bailey CJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-43 \n Bailey CJ, 2010, LANCET, V375, P2223, DOI 10.1016/S0140-6736(10)60407-2 \n Bergenstal Richard M, 2012, Diabetes Ther, V3, P13, DOI 10.1007/s13300-012-0013-8 \n Bergenstal RM, 2010, LANCET, V376, P431, DOI 10.1016/S0140-6736(10)60590-9 \n Blonde L, 2009, DIABETES OBES METAB, V11, P978, DOI 10.1111/j.1463-1326.2009.01080.x \n Bolinder J, 2012, J CLIN ENDOCR METAB, V97, P1020, DOI 10.1210/jc.2011-2260 \n Bolli G, 2009, DIABETES OBES METAB, V11, P589, DOI 10.1111/j.1463-1326.2008.01023.x \n Bonnet F, 2018, DIABETES METAB, V44, P457, DOI 10.1016/j.diabet.2018.09.005 \n Bonnet F, 2017, DIABETES METAB, V43, P299, DOI 10.1016/j.diabet.2017.04.004 \n Bosi E, 2007, DIABETES CARE, V30, P890, DOI 10.2337/dc06-1732 \n Buse JB, 2020, DIABETOLOGIA, V63, P221, DOI 10.1007/s00125-019-05039-w \n Cai XL, 2019, CHINESE MED J-PEKING, V132, P1, DOI 10.1097/CM9.0000000000000012 \n Cai XL, 2018, J DIABETES INVEST, V9, P850, DOI 10.1111/jdi.12760 \n Cai XL, 2015, J DIABETES, V7, P347, DOI 10.1111/1753-0407.12196 \n Cefalu WT, 2013, LANCET, V382, P941, DOI 10.1016/S0140-6736(13)60683-2 \n Charbonnel B, 2013, DIABETOLOGIA, V56, P1503, DOI 10.1007/s00125-013-2905-1 \n Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706 \n Cosentino F, 2020, EUR HEART J, V41, P255, DOI 10.1093/eurheartj/ehz486 \n Craddy P, 2014, DIABETES THER, V5, P1, DOI 10.1007/s13300-014-0061-3 \n Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI 10.1007/s00125-018-4729-5 \n DeFronzo RA, 2010, DIABETIC MED, V27, P309, DOI 10.1111/j.1464-5491.2010.02941.x \n DeFronzo Ralph A, 2018, Endocrinol Diabetes Metab, V1, pe00016, DOI 10.1002/edm2.16 \n DeFronzo RA, 2017, NAT REV NEPHROL, V13, P11, DOI 10.1038/nrneph.2016.170 \n DeFronzo RA, 2015, DIABETES CARE, V38, P384, DOI 10.2337/dc14-2364 \n DeFronzo RA, 2009, DIABETES CARE, V32, P1649, DOI 10.2337/dc08-1984 \n DeFronzo RA, 2008, DIABETES CARE, V31, P2315, DOI 10.2337/dc08-1035 \n Demir S, 2016, J DIABETES RES, DOI 10.1155/2016/4509603 \n Derosa G, 2012, DIABETES TECHNOL THE, V14, P475, DOI 10.1089/dia.2011.0278 \n Du J, 2017, DIABETES OBES METAB, V19, P1513, DOI 10.1111/dom.12942 \n Esposito K, 2014, ENDOCRINE, V46, P43, DOI 10.1007/s12020-013-0090-0 \n Ferrannini E, 2009, DIABETES OBES METAB, V11, P157, DOI 10.1111/j.1463-1326.2008.00994.x \n Filozof C, 2010, DIABETIC MED, V27, P318, DOI 10.1111/j.1464-5491.2010.02938.x \n Filozof C, 2010, WORLD J DIABETES, V1, P19, DOI 10.4239/wjd.v1.i1.19 \n Forst T, 2010, DIABETIC MED, V27, P1409, DOI 10.1111/j.1464-5491.2010.03131.x \n Frias JP, 2016, LANCET DIABETES ENDO, V4, P1004, DOI 10.1016/S2213-8587(16)30267-4 \n Gadde KM, 2017, DIABETES OBES METAB, V19, P979, DOI 10.1111/dom.12908 \n Gallwitz B, 2012, LANCET, V380, P475, DOI 10.1016/S0140-6736(12)60691-6 \n Goke B, 2010, INT J CLIN PRACT, V64, P1619, DOI 10.1111/j.1742-1241.2010.02510.x \n Goldenberg R, 2017, DIABETES OBES METAB, V19, P394, DOI 10.1111/dom.12832 \n Goldenberg RM, 2017, CLIN THER, V39, P2438, DOI 10.1016/j.clinthera.2017.10.016 \n Goldstein BJ, 2007, DIABETES CARE, V30, P1979, DOI 10.2337/dc07-0627 \n Goodman M, 2009, HORM METAB RES, V41, P368, DOI 10.1055/s-0028-1104604 \n Haring HU, 2014, DIABETES CARE, V37, P1650, DOI 10.2337/dc13-2105 \n Handelsman Y, 2019, DIABETES OBES METAB, V21, P883, DOI 10.1111/dom.13594 \n Henry RR, 2011, ENDOCR PRACT, V17, P906, DOI 10.4158/EP.17.6.906 \n Hermans MP, 2012, CURR MED RES OPIN, V28, P1635, DOI 10.1185/03007995.2012.735646 \n Hollander P, 2018, DIABETES THER, V9, P193, DOI 10.1007/s13300-017-0354-4 \n Hong SM, 2017, DIABETES OBES METAB, V19, P654, DOI 10.1111/dom.12870 \n Inoue H, 2019, BRIT J CLIN PHARMACO, V85, P393, DOI 10.1111/bcp.13807 \n Ji L, 2015, DIABETES OBES METAB, V17, P23, DOI 10.1111/dom.12385 \n Ji LN, 2016, DIABETES OBES METAB, V18, P775, DOI 10.1111/dom.12667 \n Jones AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152428 \n Kashiwagi A, 2015, DIABETES OBES METAB, V17, P304, DOI 10.1111/dom.12331 \n Kim JH, 2016, DIABETES METAB J, V40, P230, DOI 10.4093/dmj.2016.40.3.230 \n Kim MK, 2015, DIABETES OBES METAB, V17, P309, DOI 10.1111/dom.12424 \n Kim SA, 2011, DIABETES METAB J, V35, P159, DOI 10.4093/dmj.2011.35.2.159 \n Kim YG, 2013, DIABETOLOGIA, V56, P696, DOI 10.1007/s00125-012-2827-3 \n Lavalle-Gonzalez FJ, 2013, DIABETOLOGIA, V56, P2582, DOI 10.1007/s00125-013-3039-1 \n Lim S, 2012, CLIN ENDOCRINOL, V77, P215, DOI 10.1111/j.1365-2265.2011.04240.x \n Lingvay I, 2019, LANCET DIABETES ENDO, V7, P834, DOI 10.1016/S2213-8587(19)30311-0 \n Liu Y, 2014, DIABETES OBES METAB, V16, P111, DOI 10.1111/dom.12128 \n Lu CH, 2016, J DIABETES INVEST, V7, P366, DOI 10.1111/jdi.12422 \n Ludemann J, 2015, THER ADV ENDOCRINOL, V6, P141, DOI 10.1177/2042018815595584 \n Mearns ES, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125879 \n Mishriky BM, 2018, DIABETES METAB, V44, P112, DOI 10.1016/j.diabet.2018.01.017 \n Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007 \n Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881 \n Mueller-Wieland D, 2018, DIABETES OBES METAB, V20, P2598, DOI 10.1111/dom.13437 \n Nauck MA, 2007, DIABETES OBES METAB, V9, P194, DOI 10.1111/j.1463-1326.2006.00704.x \n Nauck MA, 2009, INT J CLIN PRACT, V63, P46, DOI 10.1111/j.1742-1241.2008.01933.x \n Nauck M, 2014, DIABETES CARE, V37, P2149, DOI 10.2337/dc13-2761 \n Nauck MA, 2011, DIABETES CARE, V34, P2015, DOI 10.2337/dc11-0606 \n Odawara M, 2014, DIABETES THER, V5, P169, DOI 10.1007/s13300-014-0059-x \n Omar B, 2014, DIABETES, V63, P2196, DOI 10.2337/db14-0052 \n Pan C, 2012, DIABETES OBES METAB, V14, P737, DOI 10.1111/j.1463-1326.2012.01593.x \n Pan CY, 2017, J DIABETES, V9, P386, DOI 10.1111/1753-0407.12425 \n Pratley RE, 2018, DIABETES OBES METAB, V20, P1111, DOI 10.1111/dom.13194 \n Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8 \n Raz I, 2008, CURR MED RES OPIN, V24, P537, DOI [10.1185/030079908X260925, 10.1185/030079908X260925 ] \n Rehman MB, 2017, DIABETES METAB, V43, P48, DOI 10.1016/j.diabet.2016.09.005 \n Rhee EJ, 2013, DIABETES OBES METAB, V15, P523, DOI 10.1111/dom.12060 \n Ridderstrale M, 2014, LANCET DIABETES ENDO, V2, P691, DOI 10.1016/S2213-8587(14)70120-2 \n Rigby SP, 2010, ENDOCR PRACT, V16, P53, DOI 10.4158/EP09146.OR \n Rodbard HW, 2019, DIABETES CARE, V42, P2272, DOI 10.2337/dc19-0883 \n Roden M, 2013, LANCET DIABETES ENDO, V1, P208, DOI 10.1016/S2213-8587(13)70084-6 \n Rosenstock J, 2013, DIABETES OBES METAB, V15, P1154, DOI 10.1111/dom.12185 \n Rosenstock J, 2018, DIABETES OBES METAB, V20, P520, DOI 10.1111/dom.13103 \n Rosenstock J, 2015, DIABETES CARE, V38, P376, DOI 10.2337/dc14-1142 \n Rosenstock J, 2015, DIABETES CARE, V38, P431, DOI 10.2337/dc14-0890 \n Rosenstock J, 2012, DIABETES CARE, V35, P1232, DOI 10.2337/dc11-1926 \n Ross S, 2015, DIABETES OBES METAB, V17, P699, DOI 10.1111/dom.12469 \n Ross SA, 2012, CURR MED RES OPIN, V28, P1465, DOI 10.1185/03007995.2012.714360 \n Scheen AJ, 2020, DIABETES METAB, V46, P181, DOI 10.1016/j.diabet.2019.10.006 \n Scheen AJ, 2019, DIABETES METAB, V45, P213, DOI 10.1016/j.diabet.2019.01.008 \n Scheen AJ, 2019, DIABETES METAB, V45, P110, DOI 10.1016/j.diabet.2018.10.003 \n Scheen AJ, 2019, EXPERT OPIN DRUG SAF, V18, P295, DOI 10.1080/14740338.2019.1602116 \n Scheen AJ, 2019, CURR CARDIOL REP, V21, DOI 10.1007/s11886-019-1165-1 \n Scheen AJ, 2020, DIABETES RES CLIN PR, V159, DOI 10.1016/j.diabres.2019.05.005 \n Scheen AJ, 2019, DIABETES RES CLIN PR, V147, P169, DOI 10.1016/j.diabres.2018.10.023 \n Scheen AJ, 2018, CIRC RES, V122, P1439, DOI 10.1161/CIRCRESAHA.117.311588 \n Scheen AJ, 2015, DRUGS, V75, P33, DOI 10.1007/s40265-014-0337-y \n Scheen AJ, 2013, LANCET DIABETES ENDO, V1, P168, DOI 10.1016/S2213-8587(13)70095-0 \n Scheen AJ, 2010, DIABETES-METAB RES, V26, P540, DOI 10.1002/dmrr.1114 \n Scheen AJ, 2018, EXPERT OPIN DRUG SAF, V17, P387, DOI 10.1080/14740338.2018.1444027 \n Schernthaner G, 2015, DIABETES OBES METAB, V17, P630, DOI 10.1111/dom.12461 \n Schumm-Draeger PM, 2015, DIABETES OBES METAB, V17, P42, DOI 10.1111/dom.12387 \n Scott R, 2008, DIABETES OBES METAB, V10, P959, DOI 10.1111/j.1463-1326.2007.00839.x \n Seino Y, 2012, DIABETES OBES METAB, V14, P927, DOI 10.1111/j.1463-1326.2012.01620.x \n Shestakova MV, 2018, DIABETES RES CLIN PR, V146, P240, DOI 10.1016/j.diabres.2018.10.018 \n Shyangdan Deepson S, 2016, BMJ Open, V6, pe009417, DOI 10.1136/bmjopen-2015-009417 \n Taskinen MR, 2011, DIABETES OBES METAB, V13, P65, DOI 10.1111/j.1463-1326.2010.01326.x \n Wang WQ, 2016, J DIABETES, V8, P229, DOI 10.1111/1753-0407.12284 \n Wang ZY, 2018, DIABETES OBES METAB, V20, P113, DOI 10.1111/dom.13047 \n White JL, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472-6823-14-17 \n Wilding JPH, 2013, DIABETES OBES METAB, V15, P403, DOI 10.1111/dom.12038 \n Yang WY, 2016, J DIABETES, V8, P796, DOI 10.1111/1753-0407.12357 \n Yang WY, 2012, J DIABETES, V4, P227, DOI 10.1111/j.1753-0407.2012.00213.x \n Yang WY, 2011, DIABETES RES CLIN PR, V94, P217, DOI 10.1016/j.diabres.2011.07.035 \n Zhang JF, 2019, ARCH ENDOCRIN METAB, V63, P478, DOI 10.20945/2359-3997000000146 \n Zhang Q, 2014, DIABETES RES CLIN PR, V105, P313, DOI 10.1016/j.diabres.2014.06.006", "hasCitationDuplums" : false, "userChangeableUntil" : "2020-12-15T07:51:15.659+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 1, "ownerInstituteCount" : 6, "directInstituteCount" : 0, "authorCount" : 1, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31344855", "label" : "Scheen A. J.. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. (2020) DIABETES & METABOLISM 1262-3636 46 3 186-196", "template" : "